Lu Yao, Meng Jingjing, Yun Mingkai, Hacker Marcus, Li Xiang, Zhang Xiaoli
Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
EJNMMI Res. 2023 Sep 25;13(1):85. doi: 10.1186/s13550-023-01035-9.
Recurrent myocardial infarction (RMI) portends an unfavorable outcome, which might be related to diminished hematopoietic-inflammatory activation. We aimed to investigate the hematopoietic-inflammatory activation and the outcome in categorized patients with primary myocardial infarction (PMI) versus RMI as well as chronic stable angina (CSA) by F-FDG PET.
A total of 105 patients (88 males; 60.1 ± 9.7 years) were included. Target-to-background ratio of bone marrow (TBR) was highest in the PMI group (n = 45), intermediate in the RMI group (n = 30), and lowest in the CSA group (n = 30) (P < 0.001). RMI group exhibited larger scar, significantly reduced left ventricular ejection fraction, and enlarged end systolic volume in comparison with the PMI and CSA groups, respectively (P < 0.05). Additionally, there was a significantly positive correlation between TBR and TBR (P < 0.001). The cumulative major adverse cardiac events free survival of patients in the RMI group was lower than that in the PMI and CSA groups during a median follow-up of 16.6 months (P = 0.026).
RMI conferred relatively decreased hematopoietic-inflammatory activation compared with PMI. Patients with RMI presented subsequent enlarged myocardial scar, worsened cardiac dysfunction, aggravated remodeling, and worse outcomes than that in PMI patients.
复发性心肌梗死(RMI)预示着不良预后,这可能与造血炎症激活减弱有关。我们旨在通过F-FDG PET研究原发性心肌梗死(PMI)与RMI以及慢性稳定型心绞痛(CSA)患者的造血炎症激活情况及预后。
共纳入105例患者(88例男性;年龄60.1±9.7岁)。骨髓靶本底比值(TBR)在PMI组(n = 45)最高,RMI组(n = 30)居中,CSA组(n = 30)最低(P < 0.001)。与PMI组和CSA组相比,RMI组分别表现出更大的瘢痕、显著降低的左心室射血分数和增大的收缩末期容积(P < 0.05)。此外,TBR与TBR之间存在显著正相关(P < 0.001)。在16.6个月的中位随访期内,RMI组患者的累积无主要不良心脏事件生存率低于PMI组和CSA组(P = 0.026)。
与PMI相比,RMI的造血炎症激活相对降低。RMI患者随后出现心肌瘢痕增大、心脏功能障碍恶化、重塑加重,且预后比PMI患者更差。